![]()
15
| 3 | 2009
Klinisk Biokemi i Norden
10. Bansal S, Buring JE, Rifai N, Mora S, Sacks
FM, Ridker PM. Fasting compared with non-
fasting triglycerides and risk of cardiovascular
events in women. JAMA. 2007;298:309-316.
11. Freiberg JJ, Tybjærg-Hansen A, Jensen JS,
Nordestgaard BG. Nonfasting triglycerides
and risk of ischemic stroke in the general
population. JAMA 2008; 300: 2142-2152.
12. Zilversmit DB. Atherogenesis: a postprandial
phenomenon. Circulation 1979;60:473-85.
13. Austin MA. Plasma triglyceride and coro-
nary heart disease. Arterioscler Thromb 1991;
11:2-14.
14. Hokanson JE, Austin MA. Plasma triglyc-
eride level is a risk factor for cardiovascular
disease independent of high-density lipo-
protein cholesterol level: a meta-analysis
of population-based prospective studies.
J Cardiovasc Risk 1996; 3:213-219.
15. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson
G, Wareham N, Bingham S et al. Triglycerides
and the risk of coronary heart disease: 10,158
incident cases among 262,525 participants in
29 Western prospective studies. Circulation
2007; 115:450-458.
16. Brunzell JD, Deeb SS. Familial lipoprotein
Lipase Deficiency, Apo C-II Defiency, and
Hepatic Lipase Deficiency. In: Scriver CR,
Beaudet AL, Sly WS, Valle D, editors. The
Metabolic & Molecular Bases of Inherited
Disease. 8th ed. McGraw-Hill, 2001:
2789-2816.
17. Nordestgaard BG, Stender S, Kjeldsen K.
Reduced atherogenesis in cholesterol-fed
diabetic rabbits. Giant lipoproteins do not
enter the arterial wall. Arteriosclerosis 1988;
8:421-428.
18. Nordestgaard BG, Zilversmit DB. Large lipo-
proteins are excluded from the arterial wall
in diabetic cholesterol-fed rabbits. J Lipid Res
1988; 29:1491-1500.
19. Austin MA, McKnight B, Edwards KL,
Bradley CM, McNeely MJ, Psaty BM et
al. Cardiovascular disease mortality in
familial forms of hypertriglyceridemia:
A 20-year prospective study. Circulation
2000; 101:2777-2782.
(Fortsætter side 16)
References
1. Rifai N, Warnick GR. Lipids, lipoproteins,
apolipoproteins, and other cardiovascular
risk factors. In: Burtis CA, Ashwood ER,
Bruns DE, eds. Tietz textbook of clini-
cal chemistry and molecular diagnostics,
4th ed. Philadelphia: Elsevier Saunders,
2006:903-82.
2. Executive Summary of the Third Report
of the National Cholesterol Education
Program (NCEP) Expert Panel on Detection,
Evaluation, And Treatment of High Blood
Cholesterol In Adults (Adult Treatment Panel
III). JAMA 2001;285:2486-97.
3. Graham I, Atar D, Borch-Johnsen K, et al.
European guidelines on cardiovascular dis-
ease prevention in clinical practice: Executive
summary. Atherosclerosis 2007:194:1-45.
4. Cohn JS, McNamara JR, Cohn SD, Ordovas
JM, Schaefer EJ. Postprandial plasma lipopro-
tein changes in human subjects of different
ages. J Lipid Res 1988;29:469-79.
5. Cohn JS, McNamara JR, Schaefer EJ.
Lipoprotein cholesterol concentrations
in the plasma of human subjects as meas-
ured in the fed and fasted states. Clin Chem
1988;34:2456-9.
6. Edelstein C, Fredenrich C, Schuelke JC,
Jensen WE, Sitrin M, Iverius PH, Scanu AM.
Hypoalphalipoproteinemia: postprandial
response of subjects with preprandial normo-
triglyceridemia and hypertriglyceridemia to
various diets. Metabolism 1993;42:247-57.
7. Mora S, Rifai N, Buring JE, Ridker PM. Fasting
compared with nonfasting lipids and apolipo-
proteins for predicting incident cardiovascu-
lar events. Circulation 2008; 118:993-1001.
8. Langsted A, Freiberg JJ, Nordestgaard BG.
Fasting and nonfasting lipid levels: influence
of normal food intake on lipids, lipoproteins,
apolipoproteins, and cardiovascular risk pre-
diction. Circulation 2008; 118; 2047-2056.
9. Nordestgaard BG, Benn M, Schnohr P,
Tybjaerg-Hansen A. Nonfasting triglycerides
and risk of myocardial infarction, ischemic
heart disease, and death in men and women.
JAMA 2007;298:299-308.
